GLP-1 Cancer Data at ASCO 2026: Peptide Drug Class Tied to Lower Stage IV Risk
A Cleveland Clinic-led TriNetX analysis presented ahead of ASCO 2026 links GLP-1 agonist use to lower Stage IV progression in four cancers, while investigators call for randomized trials.